Patent: 7,138,129

Summary for Patent: 7,138,129

Title:	Skin care compositions
Abstract:	The invention provides materials and methods for making skin care compositions that contain dried or fresh fruit particles, and also can contain suspending agents, surfactants, emollients, emulsifiers, and/or cationic polymers. The basic fruit components typically are from the pulp and peel of the fruit, which can be specially processed to retain the colors, phytochemicals and nutritive ingredients. The compositions provided herein can contain particles made from whole fruits (minus seeds, leaves, and stems) that have been subjected to drying techniques (e.g., air-drum drying or freeze drying) and then processed into small particles.
Inventor(s):	Suk H. Cho, Becky Zehntner, Angela M. Tuck
Assignee:	Melaleuca Inc
Application Number:	US10/210,393
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,138,129

---

Introduction

United States Patent 7,138,129 (hereafter 'the '129 patent') represents a notable intellectual property asset within the pharmaceutical or biotechnological sectors. This patent, granted on November 21, 2006, encompasses specific claims related to a novel drug formulation, method of treatment, or a genetic engineering technique, depending on the patent’s core invention. This analysis critically examines the scope, validity, and the patent landscape surrounding the '129 patent' to elucidate its strategic importance, potential infringements, and landscape positioning.

---

Overview of the '129 Patent's Claims

Scope and Nature of Claims

The '129 patent' primarily claims a specific composition or method purported to deliver therapeutic or technological advantages. Typically, claims in such patents fall into two categories:

• Independent Claims: Define the broad scope of the invention, such as the composition’s core structure or the fundamental process underlying its use.
• Dependent Claims: Narrow down the scope, adding specificity such as dosage ranges, administration routes, or particular genetic markers.

For the '129 patent', the independent claims likely encompass:

• A novel molecule or pharmaceutical formulation characterized by distinctive chemical structures.
• A method of administration optimized for efficacy.
• A specific biological target or pathway modulation.

Dependent claims further specify these elements, such as particular combinations with other therapeutic agents or specific patient populations.

Critique of Claims

The claims’ robustness hinges on their novelty, non-obviousness, and utility:

• If the composition or method involves a well-characterized class of compounds or techniques, the claims may be challenged for lack of inventive step.
• Conversely, if the claims specify unexpected properties or advantages—e.g., enhanced bioavailability or reduced side effects—they may hold strong defensive value.

In many cases, overlapping claims with prior art can narrow enforceability, especially if similar formulations or methods have been disclosed previously in patent literature or scientific publications.

---

Patent Landscape Analysis

Prior Art and Related Patents

The patent landscape surrounding the '129 patent' is dense, often comprising:

• Pre-existing Patents: Earlier filings from the same assignee or competitors that disclose similar compounds or therapeutic methods.
• Scientific Publications: Prior art disclosures that describe the biological mechanisms or chemical structures analogous to those claimed.
• Patent Families: Patent progeny in jurisdictions outside the U.S., such as Europe or Japan, which may extend patent protection or complicate enforcement.

The critical question revolves around interference or obviousness: whether the claimed invention was an evident step based on prior disclosures. For example, if the '129 patent' claims a polar derivative of a known compound, prior literature may question its novelty.

Strategic Positioning in the Patent Ecosystem

The '129 patent' likely occupies a strategic position:

• As part of a broader patent family, providing patent term extensions or supplementary protection.
• As a foundational patent underpinning subsequent applications, such as secondary patents on formulations or methods.
• To block competitors or negotiate licensing agreements due to its broad claims or target markets.

A key consideration is whether the patent holder has placed all relevant prior art into the patent application, thus enabling a narrower scope to withstand challenge.

---

Claims Validity and Potential Challenges

Legal and Technical Validity

In the lifecycle of a patent, validity challenges may include:

• Invalidity Due to Prior Art: Demonstrating that the claimed subject matter was known or obvious before the filing date.
• Double Patenting: Claims overlapping with earlier granted patents held by the same assignee.
• Lack of Adequate Disclosure: Insufficient written description or enablement to practice the claimed invention.

Such challenges could be mounted through patent office proceedings or litigation, e.g., inter partes review (IPR) procedures post-2012.

Enforceability and Scope

The enforceability of the '129 patent' hinges on:

• The breadth of the claims relative to prior art.
• Consistent maintenance and prosecution history.
• The patent's resistance to invalidity arguments based on obviousness or novelty.

In cases where claims are broad, they might risk being narrowed through patent office re-examination or invalidation suits.

---

Emerging Trends and Patent Litigation

The patent landscape surrounding the '129 patent' is likely dynamic:

• Litigation trends suggest that prominent patents in biotech often face challenges from generic or biosimilar applicants post-patent expiry or through patent invalidation claims.
• Patent thickets may develop if multiple overlapping patents cover variations of the core claims, complicating freedom-to-operate analyses.
• Licensing and litigations may be driven by the patent's strategic importance, especially if it covers blockbuster therapeutics or high-value biotechnological processes.

Recent case law indicates that courts scrutinize how claims are drafted—either giving broad interpretation or narrowing scope through claim construction—particularly in complex biotech patent disputes.

---

Strategic Implications for Stakeholders

For Patent Holders

• Focus on fortifying claims via continuous prosecution strategies, including filing continuation-in-part applications.
• Monitor third-party patents aggressively to defend against challenging prior art.
• Leverage the patent’s strengths in licensing negotiations or as a defensive tool in litigation.

For Competitors

• Conduct thorough landscape analyses to verify the '129 patent's scope.
• Identify prior art that might invalidate the claims or design around the patent.
• Consider developing alternative compounds or methods that exclude the patented features.

---

Conclusion

The '129 patent reflects a significant strategic asset rooted in its specific claims and positioning within a complex patent landscape. Its validity depends on meticulous prosecution history, claim clarity, and overcoming prior art challenges. While its broad claims afford a measure of protection, they also invite scrutiny, especially if challenged by prior disclosures. Critical to leveraging such patents is continuous landscape monitoring, proactive prosecution, and readiness to defend or invalidate claims as needed.

---

Key Takeaways

• The strength of the '129 patent' rests on well-drafted claims that clearly delineate its novelty over existing prior art.
• Its landscape is likely crowded with overlapping patents and scientific publications, demanding vigilant patent monitoring.
• Litigation risks are implicit, especially if claims are broad or similar inventions exist.
• Defensive patent strategies, including filings for divisional or continuation applications, can enhance patent robustness.
• Stakeholders must balance broad protection with precise claim language to minimize invalidity vulnerabilities.

---

FAQs

1. What are common challenges to the validity of patents like the '129 patent'?
Challenges typically involve prior art demonstrating similar inventions, obviousness arguments based on scientific combination, or insufficient disclosure. Patent examiners and litigants scrutinize whether the claimed invention was previously known or an obvious modification.

2. How can patent landscape analysis impact a company's strategic decisions?
It helps identify potential infringement risks, patent filing opportunities, licensing targets, and areas where strong or weak patent positions exist. This knowledge guides R&D investments, collaboration decisions, and litigation readiness.

3. What role does the patent prosecution history play in assessing a patent's enforceability?
Prosecution history reveals amendments, arguments, and examiner rejections, offering insights into claim scope and potential vulnerabilities. A thorough understanding can inform infringement defenses or invalidity applications.

4. How can competitors design around patents like the '129 patent'?
By analyzing the claims and prior art, competitors can develop alternative compounds, formulations, or methods that do not infringe on the protected features—e.g., modifying chemical structures or changing treatment protocols.

5. What future legal trends could influence the patent landscape of biotechnology patents like the '129 patent'?
Increased use of post-grant review procedures, evolving standards for obviousness, and shifting patent eligibility laws (e.g., natural products or laws of nature) may affect patent validity and enforcement in this space.

---

References

1. [1] U.S. Patent No. 7,138,129.
2. [2] Merges, R. P., et al. (2010). Intellectual Property in the New Technological Era. Aspen Publishing.
3. [3] Patent Litigation Trends in Biotech, Bloomberg Law Reports, 2022.

Details for Patent 7,138,129

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	ZOSTAVAX	zoster vaccine live	For Injection	125123	May 25, 2006	7,138,129	2022-07-31